Alirocumab and cardiovascular outcomes after acute coronary syndrome

The randomized, multisite ODYSSEY OUTCOMES clinical trial examined the effect of alirocumab on cardiovascular outcomes within a year after an acute coronary syndrome. Study participants, all of whom were receiving high-intensity statin therapy, received either subcutaneous alirocumab or matching placebo every 2 weeks.

The randomized, multisite ODYSSEY OUTCOMES clinical trial examined the effect of alirocumab on cardiovascular outcomes within a year after an acute coronary syndrome. Study participants, all of whom were receiving high-intensity statin therapy, received either subcutaneous alirocumab or matching placebo every 2 weeks. Each treatment arm included 9,462 patients. The main endpoint was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Followup at a mean 2.8 years found that 9.5% of the alirocumab group and 11.1% of the controls had suffered a composite primary endpoint event, with mortality rates of 3.5% and 4.1%, respectively. The researchers concluded that, compared with placebo, alirocumab reduces the risk of recurrent ischemic cardiovascular events after an acute coronary syndrome in patients receiving high-intensity statin therapy.